{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:24:44Z","timestamp":1791548684788,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.semarthrit.2017.09.007","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T13:52:03Z","timestamp":1507816323000},"page":"689-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":142,"title":["Medication adherence among patients with gout: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"47","author":[{"given":"Lieke E.J.M.","family":"Scheepers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"van Onna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coen D.A.","family":"Stehouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja C.W.","family":"Arts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.09.007_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10654-014-9927-y","article-title":"Determinants of the prevalence of gout in the general population: a systematic review and meta-regression","volume":"30","author":"Wijnands","year":"2015","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib3","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","article-title":"Tophaceous joint disease strongly predicts hand function in patients with gout","volume":"46","author":"Dalbeth","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheumat Dis"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib5","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib6","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/rheumatology\/keq363","article-title":"Frequency and risk factors of gout flares in a large population-based cohort of incident gout","volume":"50","author":"Rothenbacher","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib9","series-title":"Arthritis Care Res (Hoboken)","article-title":"Medication adherence in gout: a systematic review","author":"De Vera","year":"2014"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1345\/aph.1K671","article-title":"Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication","volume":"43","author":"Martin","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib11","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Brit Med J"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/01.BRS.0000065484.95996.AF","article-title":"Updated method guidelines for systematic reviews in the cochrane collaboration back review group","volume":"28","author":"van Tulder","year":"2003","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib15","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00296-013-2935-5","article-title":"Allopurinol use in a New Zealand population: prevalence and adherence","author":"Horsburgh","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/ijcp.12604","article-title":"Allopurinol adherence among patients with gout: an Italian general practice database study","volume":"69","author":"Mantarro","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib17","first-page":"715","article-title":"Adherence and persistence to urate-lowering therapies in the Irish setting","author":"McGowan","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib18","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.clinthera.2012.01.020","article-title":"Evaluation of health care costs and utilization patterns for patients with gout","volume":"34","author":"Park","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib19","first-page":"44","article-title":"Patient compliance, in rheumatoid arthritis, polymyalgia rheumatica, and gout","volume":"30","author":"de Klerk","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2016.1218596","article-title":"Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting","volume":"26","author":"Lee","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1471-2474-13-174","article-title":"Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout","volume":"13","author":"Dalbeth","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/acr.20570","article-title":"Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability","volume":"63","author":"Dalbeth","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/RHU.0b013e31824e1f6f","article-title":"Living with gout in New Zealand: an exploratory study into people\u2019s knowledge about the disease and its treatment","volume":"18","author":"Martini","year":"2012","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib24","first-page":"466","article-title":"Compliance in gout patients","volume":"35","author":"Silva","year":"2010","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib25","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s10067-014-2838-1","article-title":"Health literacy in patients dealing with gout: a qualitative study","volume":"34","author":"van Onna","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12906-016-1067-3","article-title":"A cross-sectional internet-based patient survey of the management strategies for gout","volume":"16","author":"Singh","year":"2016","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib27","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kes431","article-title":"Rates of adherence and persistence with allopurinol therapy among gout patients in Israel","volume":"52","author":"Zandman-Goddard","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib28","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims","volume":"31","author":"Riedel","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/ard.2007.076182","article-title":"Uric acid lowering therapy: prescribing patterns in a large cohort of older adults","volume":"67","author":"Solomon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.140588","article-title":"Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system","volume":"42","author":"Rashid","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","article-title":"Comparison of drug adherence rates among patients with seven different medical conditions","volume":"28","author":"Briesacher","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib32","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1185\/03007990903017966","article-title":"Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis","volume":"25","author":"Halpern","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/ard.2008.092619","article-title":"Opportunities for improving medication use and monitoring in gout","volume":"68","author":"Singh","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib34","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.amjmed.2009.05.026","article-title":"The dynamics of chronic gout treatment: medication gaps and return to therapy","volume":"123","author":"Harrold","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib36","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00296-015-3284-3","article-title":"Patient and clinical characteristics associated with gout flares in an integrated healthcare system","volume":"35","author":"Rashid","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib37","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2165\/11537400-000000000-00000","article-title":"Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices","volume":"28","author":"Shi","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12160-014-9595-x","article-title":"Does electronic monitoring influence adherence to medication? Randomized controlled trial of measurement reactivity","volume":"48","author":"Sutton","year":"2014","journal-title":"Ann Behav Med"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12160-014-9595-x","article-title":"Does electronic monitoring influence adherence to medication? Randomized controlled trial of measurement reactivity","volume":"48","author":"Sutton","year":"2014","journal-title":"Ann Behav Med"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib41","unstructured":"Sabat\u00e9 E. Adherence to Long-Term Therapies: Evidence for Action: World Health Organization; 2003."},{"key":"10.1016\/j.semarthrit.2017.09.007_bib42","first-page":"1","article-title":"Plasma oxypurinol as a measure of adherence in clinical trials","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib43","first-page":"266","article-title":"Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care\u20145-year follow-up of a proof-of-concept study","volume":"56","author":"Abhishek","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2017.09.007_bib44","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/ar2659","article-title":"Adherence with urate-lowering therapies for the treatment of gout","volume":"11","author":"Harrold","year":"2009","journal-title":"Arthritis Res Ther"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217303190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017217303190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T10:47:02Z","timestamp":1530269222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017217303190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0049017217303190"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.09.007","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medication adherence among patients with gout: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}